Libtayo Approved for Advanced NSCLC With High PD-L1 Expression
The FDA approved cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) for the first-line treatment of patients with metastatic or locally advanced or metastatic non-small cell lung cancer (NSCLC) that is unresectable and not amenable to definitive chemoradiation whose tumors have high PD-L1 expression and no EGFR, ALK or ROS1 aberrations.